Recruiting Pulmonary Hypertension Studies in Sylmar
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment....
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex media...
About Pulmonary Hypertension Clinical Trials in Sylmar
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Sylmar, CA. These studies are seeking a combined 346 participants. Research is being sponsored by Novartis Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Sylmar — FAQ
Are there pulmonary hypertension clinical trials in Sylmar?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Sylmar, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Sylmar?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sylmar research site will contact you about next steps.
Are clinical trials in Sylmar free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sylmar studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Sylmar are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov